OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI)

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals logoOncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OGXI
  • CUSIP: 68230A10
Key Metrics:
  • Previous Close: $0.57
  • 50 Day Moving Average: $0.82
  • 200 Day Moving Average: $0.86
  • 52-Week Range: $0.46 - $3.38
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $17.11M
  • Outstanding Shares: 30,009,000
  • Beta: 1.79
Additional Links:
Companies Related to OncoGenex Pharmaceuticals:

Analyst Ratings

Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.33 (484.80% upside)

Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Show:
DateFirmActionRatingPrice TargetDetails
1/22/2016Needham & Company LLCLower Price TargetBuy$6.00 -> $3.00View Rating Details
1/21/2016Royal Bank Of CanadaLower Price TargetSector Perform$1.60 -> $1.00View Rating Details
12/2/2015Stifel NicolausDowngradeBuy -> HoldView Rating Details
9/24/2015William BlairReiterated RatingBuy$6.00View Rating Details
(Data available from 8/31/2014 forward)

Earnings

Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/4/2016Q216($0.22)($0.23)$1.17 million$2.10 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details
3/9/2016Q4($0.15)($0.06)ViewN/AView Earnings Details
11/12/2015Q3($0.17)($0.16)ViewListenView Earnings Details
8/13/2015Q2$0.34($0.26)ViewListenView Earnings Details
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details
10/30/2014($0.38)($0.23)ViewN/AView Earnings Details
8/7/2014($0.55)($0.47)ViewN/AView Earnings Details
4/30/2014($0.50)($0.59)ViewN/AView Earnings Details
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016John BencichCFOSell1,380$0.57$786.60View SEC Filing  
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.11View SEC Filing  
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68View SEC Filing  
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.82View SEC Filing  
3/15/2016John BencichCFOSell834$0.83$692.22View SEC Filing  
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39View SEC Filing  
8/18/2015John BencichCFOSell1,427$2.76$3,938.52View SEC Filing  
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.50View SEC Filing  
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.50View SEC Filing  
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View SEC Filing  
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View SEC Filing  
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View SEC Filing  
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateHeadline
News IconCrowd Ratings & Broker Views on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)? - Post News (NASDAQ:OGXI)
www.kentuckypostnews.com - August 22 at 6:35 PM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul (NASDAQ:OGXI)
biz.yahoo.com - August 22 at 6:35 PM
News IconBiotech Stocks Worth a Closer Look: OncoGenex Pharmaceuticals ... - The Voice Registrar (NASDAQ:OGXI)
voiceregistrar.com - August 20 at 10:42 AM
News Icon2 Biotech Stocks News And Price Trends: OncoGenex ... - The Voice Registrar (NASDAQ:OGXI)
voiceregistrar.com - August 20 at 10:42 AM
streetinsider.com logoOncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in Metastatic CRPC (NASDAQ:OGXI)
www.streetinsider.com - August 17 at 6:55 PM
finance.yahoo.com logoBiotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data (NASDAQ:OGXI)
finance.yahoo.com - August 17 at 6:55 PM
News IconHealthcare Eyes Catching Stocks in Verities- StemCells Inc. (NASDAQ:STEM), OncoGenex Pharmaceuticals (NASDAQ ... - Seneca Globe (NASDAQ:OGXI)
www.senecaglobe.com - August 17 at 9:41 AM
News IconFrontline Matters in Notice- OncoGenex Pharmaceuticals (NASDAQ:OGXI), Northern Oil and Gas (NYSE:NOG), Teekay ... - Seneca Globe (NASDAQ:OGXI)
www.senecaglobe.com - August 17 at 9:41 AM
istreetwire.com logoMomentum Stocks: Urban Outfitters Inc. (URBN), OncoGenex Pharmaceuticals, Inc. (OGXI), Laredo Petroleum, Inc. (LPI) - iStreetWire (NASDAQ:OGXI)
istreetwire.com - August 17 at 9:41 AM
streetinsider.com logoOncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in Metastatic CRPC - StreetInsider.com (NASDAQ:OGXI)
www.streetinsider.com - August 17 at 9:41 AM
bizjournals.com logoBothell-based biotech OnoGenex explores strategic alternatives after clinical trial fails (NASDAQ:OGXI)
www.bizjournals.com - August 16 at 6:47 PM
News IconOncoGenex (OGXI) Stock Nosedives after Failing Yet Another Trial (NASDAQ:OGXI)
www.economiccalendar.com - August 16 at 6:47 PM
feeds.reuters.com logoUPDATE 1-OncoGenex seeks strategic alternatives after drug study fails (NASDAQ:OGXI)
feeds.reuters.com - August 16 at 10:22 AM
streetinsider.com logoForm 8-K ONCOGENEX PHARMACEUTICAL For: Aug 16 (NASDAQ:OGXI)
www.streetinsider.com - August 16 at 9:54 AM
publicnow.com logoOncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer (NASDAQ:OGXI)
www.publicnow.com - August 16 at 9:54 AM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:OGXI)
biz.yahoo.com - August 16 at 9:54 AM
finance.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Financials (NASDAQ:OGXI)
finance.yahoo.com - August 13 at 6:18 PM
ftsenews.co.uk logoOncoGenex Pharmaceuticals Inc. (OGXI) Updated Price Targets - FTSE News (NASDAQ:OGXI)
www.ftsenews.co.uk - August 9 at 9:48 AM
finance.yahoo.com logoEdited Transcript of OGXI earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:OGXI)
finance.yahoo.com - August 6 at 6:42 PM
prnewswire.com logoOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 - PR Newswire (press release) (NASDAQ:OGXI)
www.prnewswire.com - August 4 at 7:03 PM
publicnow.com logoOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 (NASDAQ:OGXI)
www.publicnow.com - August 4 at 7:03 PM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen (NASDAQ:OGXI)
biz.yahoo.com - August 4 at 7:03 PM
biz.yahoo.com logoQ2 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:OGXI)
biz.yahoo.com - August 4 at 9:47 AM
News IconEquity Roundup: Stock Performance Focus on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Press Telegraph (NASDAQ:OGXI)
presstelegraph.com - July 23 at 10:34 AM
capitalcube.com logoETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : July 22, 2016 (NASDAQ:OGXI)
www.capitalcube.com - July 22 at 3:18 PM
News IconOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:OGXI)
www.engelwooddaily.com - July 22 at 9:35 AM
News IconOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Short Interest Decreased By 4.48% - Consumer Eagle (NASDAQ:OGXI)
www.consumereagle.com - July 22 at 9:35 AM
news.cmlviz.com logoOncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) Stock Technicals Hit Extreme Weakness - CML News (NASDAQ:OGXI)
news.cmlviz.com - July 22 at 9:35 AM
finance.yahoo.com logoOncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:OGXI)
finance.yahoo.com - July 21 at 4:01 PM
News IconWere Analysts Bearish OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) This Week? - Consumer Eagle (NASDAQ:OGXI)
www.consumereagle.com - July 19 at 6:43 PM
news.cmlviz.com logoOncoGenex Pharmaceuticals, Inc. (NasdaqCM:OGXI) Fundamental Star Rating Report - CML News (NASDAQ:OGXI)
news.cmlviz.com - July 19 at 6:43 PM
News IconOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:OGXI)
telanaganapress.com - July 18 at 12:02 PM
News IconShares Moving Down on the Week: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Engelwood Daily (NASDAQ:OGXI)
www.engelwooddaily.com - July 17 at 6:00 PM
News IconOncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:OGXI)
www.engelwooddaily.com - July 15 at 11:31 AM
News IconWall Street Ratings and Target Price Views on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Telanagana Press (NASDAQ:OGXI)
telanaganapress.com - July 13 at 9:34 AM
News IconHow Analysts Feel About OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)? - Consumer Eagle (NASDAQ:OGXI)
www.consumereagle.com - July 12 at 10:55 AM
investornewswire.com logoEarnings Surprise in Focus: OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Investor Newswire (NASDAQ:OGXI)
www.investornewswire.com - July 9 at 9:48 AM
News IconCan OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:OGXI)
www.engelwooddaily.com - July 7 at 9:33 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead OncoGenex Pharmaceuticals Inc. (OGXI) - Fiscal Standard (NASDAQ:OGXI)
www.fiscalstandard.com - July 6 at 11:15 AM
capitalcube.com logoETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : June 30, 2016 (NASDAQ:OGXI)
www.capitalcube.com - June 30 at 12:25 PM
News IconOncogenex Pharmaceuticals Incorporated (NASDAQ:OGXI) Shorts Decreased by 16.46% After Short Covering - Engelwood Daily (NASDAQ:OGXI)
www.engelwooddaily.com - June 29 at 6:31 PM
News IconCovering the Bases on OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI): Where is the Stock Going? - Press Telegraph (NASDAQ:OGXI)
presstelegraph.com - June 29 at 6:31 PM
finance.yahoo.com logoForget Valeant, Invest in These Attractive Drug Stocks Instead (NASDAQ:OGXI)
finance.yahoo.com - June 28 at 3:52 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For OncoGenex Pharmaceuticals Inc. (OGXI) - Fiscal Standard (NASDAQ:OGXI)
www.fiscalstandard.com - June 27 at 6:36 PM
ftsenews.co.uk logoNew Broker Ratings For OncoGenex Pharmaceuticals Inc. (OGXI) - FTSE News (NASDAQ:OGXI)
www.ftsenews.co.uk - June 24 at 6:36 PM
fiscalstandard.com logoOncoGenex Pharmaceuticals Inc. (OGXI) Current Analyst Ratings - Fiscal Standard (NASDAQ:OGXI)
www.fiscalstandard.com - June 23 at 9:18 AM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events (NASDAQ:OGXI)
biz.yahoo.com - June 20 at 8:01 AM
streetupdates.com logoTwo Stocks within Traders Observation: Minerva Neurosciences, Inc (NASDAQ:NERV) , OncoGenex Pharmaceuticals ... - Street Updates (NASDAQ:OGXI)
www.streetupdates.com - June 7 at 6:51 PM
istreetwire.com logoOncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) Earns Consensus Hold Rating - iStreetWire (NASDAQ:OGXI)
istreetwire.com - June 6 at 6:32 PM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:OGXI)
www.sharetrading.news - June 6 at 10:19 AM

Social

OncoGenex Pharmaceuticals (NASDAQ:OGXI) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff